Tyrosine kinase inhibitors (TKIs) have transformed the treatment of non-small cell lung cancer (NSCLC), especially in cases driven by specific genetic mutations [1,2]. Rearranged during Transfection (RET) is a proto-oncogene located on chromosome 10q11.2 that encodes a receptor tyrosine kinase necessary for cell survival, proliferation, migration, and differentiation [3]. The gene discussed is RET; the disease is non-small cell lung carcinoma.